Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142734 | 1.00 | LMNA (0.58) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL2646824 | 1.00 | LMNA (0.58) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL13618128 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL14617628 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL2525369 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL2525365 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL14019069 | 0.87 | LMNA (0.66) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL5019087 | 0.87 | LMNA (0.61) | LMNASMN1; SMN2HTTSLC1A3SLC1A1 | |
| SCHEMBL8132360 | 0.85 | CTSS (0.53) | LMNASMN1; SMN2HTTCTSLCTSS | |
| SCHEMBL8274264 | 0.85 | LMNA (0.56) | LMNASMN1; SMN2HTTCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4655292-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | Ab2 Therapeutics, S. L. (ES) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024156892-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | ABAC Therapeutics, S.L. (ES) | 2024-08-02 | — | — | WO | disclosed |
| EP-4406945-A1 | NEW COMPOUNDS FOR TREATING STREPTOCOCCUS INFECTIONS | ABAC THERAPEUTICS, S.L. (ES) | 2024-07-31 | — | — | EP | disclosed |
| US-8653041-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653041-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653041-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8318685-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318685-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-4288547-A | CULTURING NUTRIENT MEDIUM CONTAINING D-STREPTAMINE WITH MICROMONOSPORA PURPUREA | SANOFI S.A. (FR) | 1981-09-08 | — | — | US | disclosed |
| US-4231945-A | BACTERICIDES | SCHERING CORPORATION (US) | 1980-11-04 | — | — | US | disclosed |
| US-4212859-A | OXIMINATION OF AMINO PRECURSOR, ACID HYDROLYSIS, REDUCTION OF OXO GROUP | SCHERING CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
| US-4212860-A | COUPLING THE PENTOFURANOSYL ONTO THE PROTECTED CYCLITOL | SCHERING CORPORATION (US) | 1980-07-15 | — | — | US | disclosed |
| EP-0000473-A1 | Process for preparing aminoglycoside derivatives, novel derivatives obtained and pharmaceutical compositions containing such derivatives | Technobiotic Ltd. (CH) | 1979-02-07 | — | — | EP | disclosed |
| US-4125706-A | Novel process for the preparation of 1-N-(alpha-substituted-omega-aminoacyl)-3'-deoxyribostamycin | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1978-11-14 | — | — | US | disclosed |
| US-4117221-A | AMINOACYL DERIVATIVES OF AMINOGLYCOSIDE ANTIBIOTICS | SCHERING CORPORATION (US) | 1978-09-26 | — | — | US | disclosed |
| US-4065616-A | ANTIBIOTICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-12-27 | — | — | US | disclosed |
| US-4028188-A | MICROMONOSPORA PURPUREA | STERLING DRUG INC. (US) | 1977-06-07 | — | — | US | disclosed |
| US-3972930-A | Aminocyclitol antibiotics | STERLING DRUG INC. (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178438-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | NQO2, NQO1, MRPL21 | LMNA 2043/4885SMN1; SMN2 3029/4885HTT 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.